Linagliptin Zentiva

Linagliptin, the active ingredient in Linagliptin Zentiva, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet, exercise and regular monitoring of blood glucose levels.

GNH USA supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established distribution networks and quality assurance processes.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): provides glycaemic control when used alone in patients inadequately controlled by diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin or other antidiabetic agents. - Type 2 diabetes mellitus (adjunct to lifestyle): supports blood sugar management as part of a comprehensive plan that includes diet, exercise and weight control.

Linagliptin may cause adverse reactions ranging from mild to serious.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Bullous skin disorders: blistering conditions such as bullous pemphigoid.

Before prescribing Linagliptin, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor patients with existing heart conditions. - Elderly patients: consider lower starting dose due to potential sensitivity. - Concomitant drugs: review all medications for possible interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Linagliptin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampin or other potent enzyme inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance risk of dehydration. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - NSAIDs: increased risk of renal impairment when combined.